You have full access to this open access article. Vulvar lichen sclerosus VLS is an underestimated chronic disease.
It can cause significant symptom burden and sexual dysfunction. This study aimed to evaluate patient satisfaction and current challenges in the management of VLS in a certified dysplasia unit, particularly during the COVID pandemic. The questionnaire contained 43 questions on general treatment, diagnostic delays, disease education, psychologic and sexual issues, and specific questions regarding the COVID pandemic. The questionnaires were distributed between January and September This study included patients diagnosed with VLS, who were treated at our certified dysplasia unit.
Most participants reported psychologic problems There was a general request for booklets to inform and educate the patients about their disease. Furthermore, the respondents demanded a telephone hotline to answer the questions and wished for follow-up visits via e-mail to cope better with their current situation. This study highlights the need for more effective treatments for VLS and an increased awareness of psychologic and sexual distress.
To ensure patient well-being and satisfaction, it is imperative to offer individualized care with adequate disease education in a team of specialists from various disciplines. The survey analysis of vulvar lichen sclerosus patients in a DKG-certified dysplasia unit highlights the need for more effective treatments for VLS and increased awareness of psychological and sexual distress. Vulvar lichen sclerosus VLS is a chronic inflammatory disease of the skin and mucous membranes that is characterized by a lichenoid inflammatory pattern.
This inflammatory reaction leads to fibrosis and scarring during the disease and can lead to loss of function [ 1 ]. Women and girls commonly report itching, burning pain, and anal or genital bleeding due to fissuring of affected tissues.
